Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06588283
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-04
Brief Title:
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight A Phase 3b Randomized Multicenter Open-Label Study TOGETHER-PsO
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TOGETHER-PsO
Brief Summary:
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight receive ixekizumab and tirzepatide concomitantly administered participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab
Participation in this study includes up to 12 visits and could last up to 61 weeks including screening open label treatment period and post-treatment follow-up period
Participation in this study includes up to 12 visits and could last up to 61 weeks including screening open label treatment period and post-treatment follow-up period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None